Bio-Rad Reliance RT-PCR COVID assays granted EUA

Create PDF

April 2021—Bio-Rad Laboratories announced that its Reliance SARS-CoV-2/FluA/FluB RT-PCR and Reliance SARS-CoV-2 RT-PCR assay kits were granted emergency use authorization by the FDA.

The multi-target Reliance SARS-CoV-2/FluA/FluB RT-PCR assay kit simultaneously detects and differentiates SARS-CoV-2, influenza A, and influenza B in a single multiplex reaction. The highly sensitive respiratory pathogen panel is intended for use with nasopharyngeal swabs and anterior nasal swabs. The assay kit includes Bio-Rad positive and negative molecular controls.

The Reliance SARS-CoV-2 RT-PCR assay kit is a multiplex test that targets two separate regions in the nucleocapsid gene (N1 and N2) to ensure greater sensitivity and tolerance to potential mutations. The kit contains the company’s standard and negative molecular controls.